中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

166 records (took 0.044 seconds)

    CATALYTIC CONVERTER, A KIT FOR SERVICING A CATALYTIC CONVERTER, AND METHOD FOR SERVICING A CATALYTIC CONVERTER
    1.
    发明申请
    CATALYTIC CONVERTER, A KIT FOR SERVICING A CATALYTIC CONVERTER, AND METHOD FOR SERVICING A CATALYTIC CONVERTER 审中-公开
    催化转化器，用于维修催化转化器的工具包和用于维修催化转化器的方法

    公开(公告)号：WO2014018883A1

    公开(公告)日：2014-01-30

    申请号：PCT/US2013/052321

    申请日：2013-07-26

    Applicant: SERVAAS LABORATORIES, INC.

    Inventor： SERVAAS, Paul ,  MILLER, Ryan, Scott

    IPC: F01N3/24 ,  F01N3/28 ,  B01D53/94 ,  B60S5/00

    CPC classification number: F01N3/28 ,  B01D53/94 ,  B01D53/96 ,  F01N3/10 ,  F01N3/206 ,  F01N13/18 ,  F01N2260/04 ,  F01N2450/00 ,  Y02T10/24 ,  Y10T29/49345 ,  Y10T29/49826

    Abstract: A method is disclosed. The method comprises the steps of preparing a serviceable catalytic converter (108) such that a catalyst substrate (144) of the catalytic converter (108) is serviceable while the catalytic converter (108) remains connected to an exhaust system (100) by forming a lower surface (108b) of the body (124) of the catalytic converter (108) with an absence of material in order to provide at least one opening (148, 148a, 148b) in the lower surface (108b) of the body (124) of the catalytic converter (108) for permitting selective access to a fluid- flow passage (136) that extends through the body (124) of the catalytic converter (108) that contains the catalyst substrate (144); and disposing at least one close-out member (175, 175a, 175b) in the at least one opening (148, 148a, 148b) for fluidly-sealing the at least one opening (148, 148a, 148b). A component (108) of an exhaust system (100) that is serviceable while remaining fluidly-connected and physically-connected to the exhaust system (100) is also disclosed. A kit (K) for servicing a component (108) of an exhaust system (100) that is serviceable while remaining fluidly-connected and physically-connected to the exhaust system (100) is also disclosed.

    Abstract translation: 公开了一种方法。 该方法包括以下步骤：制备可使用的催化转化器（108），使得催化转化器（108）的催化剂基底（144）可使用，同时催化转化器（108）保持与排气系统（100）连接，形成 催化转化器（108）的主体（124）的下表面（108b）没有材料，以便在主体（124）的下表面（108b）中提供至少一个开口（148,148a，148b） ），用于允许选择性地进入延伸穿过包含催化剂衬底（144）的催化转化器（108）的主体（124）的流体流动通道（136）; 以及在所述至少一个开口（148,148a，148b）中设置至少一个闭合构件（175,175a，175b），用于流体地密封所述至少一个开口（148,148a，148b）。 还公开了一种能够在保持流体连接并物理连接到排气系统（100）的同时可使用的排气系统（100）的部件（108）。 还公开了一种用于维修排气系统（100）的组件（108）的工具（K），其可以在保持流体连接并物理连接到排气系统（100）的同时可使用。

    PHARMACEUTICL COMPOSITIONS FOR THE TREATMENT OF CFTR -MEDIATED DISORDERS
    2.
    发明申请
    PHARMACEUTICL COMPOSITIONS FOR THE TREATMENT OF CFTR -MEDIATED DISORDERS 审中-公开
    用于治疗CFTR相关疾病的药物组合物

    公开(公告)号：WO2013185112A1

    公开(公告)日：2013-12-12

    申请号：PCT/US2013/044838

    申请日：2013-06-07

    Applicant: VERTEX PHARMACEUTICALS INCORPORATED

    Inventor： VAN GOOR, Fredrick, F.

    IPC: A61K31/404 ,  A61K31/44 ,  A61K31/47 ,  A61P43/00

    CPC classification number: C07D215/56 ,  A61K9/08 ,  A61K9/1617 ,  A61K9/1652 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/4858 ,  A61K9/4866 ,  A61K31/404 ,  A61K31/443 ,  A61K31/47 ,  A61K45/06 ,  A61K47/10 ,  A61K47/26 ,  A61K47/32 ,  A61K47/38 ,  C07D405/12 ,  A61K2300/00

    Abstract: The present invention relates to the use of N-[2,4-bis(1,1-dimethylethyl)-5- hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxaraide (Compound 1), solids forms, and pharmaceutical compositions thereof for the treatment of CFTR-mediated diseases, particularly cystic fibrosis, in patients possessing specific genetic mutations. The present invention also relates to the use of Compound ί in combination with 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxoI- 5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound 2), and Compound 1 in combination with (S)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3- dihydroxypropyl)~6~fluoro-2-( 1 -hydroxy-2-methylpropan-2-yl)- 1H-indol-5- yl)cyclopropanecarboxamide (Compound 3), for the treatment of CFTR-mediated diseases, particularly cystic fibrosis, in patients possessing specific genetic mutations. The present invention also relates to solid forms and formulations of Compound 2 or Compound 3 in combination with Compound 1, and pharmaceutical compositions thereof, for the treatment of CFTR-mediated diseases, particularly cystic fibrosis, in patients possessing specific genetic mutations.

    Abstract translation: 本发明涉及使用N- [2,4-双（1,1-二甲基乙基）-5-羟基苯基] -1,4-二氢-4-氧代喹啉-3-甲酰胺（化合物1），固体形式， 及其药物组合物，用于治疗具有特定遗传突变的患者中CFTR介导的疾病，特别是囊性纤维化。 本发明还涉及化合物I与3-（6-（1-（2,2-二氟苯并[d] [1,3]二氧代-5-基）环丙烷甲酰氨基）-3-甲基吡啶-2 - 基）苯甲酸（化合物2）和化合物1与（S）-1-（2,2-二氟苯并[d] [1,3]二氧杂环戊烯-5-基）-N-（1-（2 ，3-二羟丙基）-6-氟-2-（1-羟基-2-甲基丙-2-基）-1H-吲哚-5-基）环丙烷甲酰胺（化合物3），用于治疗CFTR介导的疾病，特别是 囊性纤维化，具有特异性遗传突变的患者。 本发明还涉及化合物2或化合物3与化合物1组合的固体形式和制剂及其药物组合物，用于治疗具有特定遗传突变的患者的CFTR介导的疾病，特别是囊性纤维化。

    ELECTRON IMPACT ION SOURCE WITH FAST RESPONSE
    3.
    发明申请
    ELECTRON IMPACT ION SOURCE WITH FAST RESPONSE 审中-公开
    电子影响离子源与快速反应

    公开(公告)号：WO2013163530A2

    公开(公告)日：2013-10-31

    申请号：PCT/US2013/038388

    申请日：2013-04-26

    Applicant: LECO CORPORATION

    Inventor： VERENCHIKOV, Anatoly, N.

    IPC: H01J49/14

    CPC classification number: H01J49/147 ,  G01N30/7206 ,  H01J49/0468 ,  H01J49/40

    Abstract: A closed electron impact ion source with overall opening area of less than 30mm 2 is employed for direct and pulsed extraction into a time-flight mass spectrometer in order to enhance sensitivity and immunity to chemical noise of oil and fumes of the vacuum system. For compatibility with dual stage GCxGC separation, the source may contain an inert liner surrounded by an isothermal cage of thermally conductive material. The source inner surface may be reduced to under 100mm 2 . A portion of carrier gas may be pumped down before admitting the sample and carrier gas into the source. A cooled surface may be used to condense fumes at the analysis time.

    Abstract translation: 整个开口面积小于30mm2的封闭电子冲击离子源用于直接和脉冲提取到时间飞行质谱仪中，以提高真空系统的油和烟雾的化学噪声的灵敏度和抗扰性。 为了与双级GCxGC分离兼容，源可以包含被导热材料的恒温笼包围的惰性衬垫。 源内表面可以减少到100mm2以下。 在将样品和载气进入源之前，可以将一部分载气抽出。 冷却的表面可用于在分析时间浓缩烟雾。

    VIRAL DYNAMIC MODEL FOR HCV COMBINATION THERAPY
    8.
    发明申请
    VIRAL DYNAMIC MODEL FOR HCV COMBINATION THERAPY 审中-公开
    HCV组合治疗的病毒动态模型

    公开(公告)号：WO2011156545A1

    公开(公告)日：2011-12-15

    申请号：PCT/US2011/039712

    申请日：2011-06-09

    Applicant: VERTEX PHARMACEUTICALS INCORPORATED ,  ADIWIJAYA, Bambang, Senoaji ,  CARON, Paul, R. ,  GARG, Varun ,  KIEFFER, Tara, Lynn ,  KWONG, Ann Dak-Yee ,  KAUFFMAN, Robert, S.

    Inventor： ADIWIJAYA, Bambang, Senoaji ,  CARON, Paul, R. ,  GARG, Varun ,  KIEFFER, Tara, Lynn ,  KWONG, Ann Dak-Yee ,  KAUFFMAN, Robert, S.

    IPC: G01N33/576 ,  G06F19/00

    CPC classification number: G01N33/5767

    Abstract: A model of HCV dynamics to quantify responses in subjects dosed with a combination of PR and a protease inhibitor is provided. The model quantitatively predicts clinical outcomes of alternative durations of the protease inhibitor and PR, and these predictions correspond well to the empirically observed outcomes in clinical trials. This model accounts for multiple HCV variants with reduced replicative fitness and susceptibility to protease inhibitors, and examines how these properties of the variants contribute to the HCV dynamics in subjects dosed with the triple combination therapy. Furthermore, the model provides insight into the mechanisms of how protease inhibitor-based regimens increase the SVR rate and reduce total duration of treatment, and predicts that the protease inhibitor-mediated reduction in the overall fitness of the HCV quasispecies, along with potential synergy of protease inhibitors and PR, may enable previous PR nonresponders to achieve SVR on T/PR treatment.

    Abstract translation: 提供了HCV动力学模型，用于定量给予PR和蛋白酶抑制剂组合的受试者的反应。 该模型定量预测了蛋白酶抑制剂和PR的替代持续时间的临床结果，这些预测与临床试验中经验观察到的结果很好地吻合。 该模型考虑了多种HCV变异体，其具有降低的复制适应性和对蛋白酶抑制剂的易感性，并且检查这些变体的这些性质如何有助于用三联组合治疗的受试者的HCV动态。 此外，该模型提供了对蛋白酶抑制剂方案如何增加SVR率和减少治疗总持续时间的机制的了解，并预测蛋白酶抑制剂介导的HCV准种总体适应性的降低以及潜在的协同作用 蛋白酶抑制剂和PR，可以使先前的PR无应答者在T / PR治疗上实现SVR。

    DIMERIC OXIDATION-RESISTANT APOLIPOPROTEIN A1 VARIANTS
    9.
    发明申请
    DIMERIC OXIDATION-RESISTANT APOLIPOPROTEIN A1 VARIANTS 审中-公开
    二氧化硫抗氧化蛋白A1变体

    公开(公告)号：WO2011143362A1

    公开(公告)日：2011-11-17

    申请号：PCT/US2011/036144

    申请日：2011-05-11

    Applicant: ESPERION THERAPEUTICS, INC. ,  NEWTON, Roger, S. ,  SRIVASTAVA, Ajit, K. ,  HURLEY, Tim ,  CRAMER, Clay ,  FILIPPOV, Sergey, V. ,  PINKOSKY, Stephen, L.

    Inventor： NEWTON, Roger, S. ,  SRIVASTAVA, Ajit, K. ,  HURLEY, Tim ,  CRAMER, Clay ,  FILIPPOV, Sergey, V. ,  PINKOSKY, Stephen, L.

    IPC: A61K38/17 ,  C07K14/775

    CPC classification number: C07K14/775 ,  A61K38/00

    Abstract: An isolated oxidation-resistant ApoA1 variant dimer includes a first oxidation-resistant ApoA1 variant polypeptide monomer and a second oxidation-resistant ApoA1 variant polypeptide monomer, wherein at least one of the first and the second monomers comprises at least one amino acid substitution of a tryptophan residue for an oxidation resistant amino acid, or a functional fragment or variant thereof. Methods for treating a disease or disorder comprises administering to a subject in need thereof, a therapeutically effective amount of an isolated oxidation-resistant ApoA1 variant dimer, an oxidation-resistant ApoA1 variant monomer, an oxidation-resistant ApoA1 monomer -lipid complex, a lipid complexed oxidation-resistant ApoA1 variant monomer, a lipid complexed oxidation-resistant ApoA1 variant dimer, or combinations thereof to the subject to enhance cholesterol efflux activity in the presence of an oxidant.

    Abstract translation: 分离的抗氧化ApoA1变体二聚体包括第一抗氧化ApoA1变体多肽单体和第二抗氧化ApoA1变体多肽单体，其中第一和第二单体中的至少一个包含至少一个色氨酸的氨基酸取代 用于抗氧化氨基酸的残基或其功能片段或变体。 用于治疗疾病或病症的方法包括向有需要的受试者施用治疗有效量的分离的抗氧化ApoA1变体二聚体，抗氧化ApoA1变体单体，抗氧化ApoA1单体脂质复合物，脂质 复合抗氧化ApoA1变体单体，脂质复合抗氧化ApoA1变体二聚体或其组合，以增强氧化剂存在下的胆固醇流出活性。

Patent Agency Ranking